We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $143M
1-Year Est. Return 773.18%
This Fund
S&P 500
This Quarter Est. Return
+24.75%
1 Year Est. Return
+773.18%
3 Year Est. Return
+7,269.42%
5 Year Est. Return
+14,284.66%
10 Year Est. Return
+1,769,765.59%
AUM
$562M
AUM Growth
-$50.5M
Cap. Flow
-$13.3M
Cap. Flow %
-2.37%
Top 10 Hldgs %
67.51%
Holding
88
New
30
Increased
9
Reduced
14
Closed
29

Top Buys

Rank Stock Value
1
KDMN
Kadmon Holdings, Inc.
KDMN
+$12.1M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$6.11M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$5.66M
4
OBSV
ObsEva SA Ordinary Shares
OBSV
+$5.64M
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$5.08M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$22.1M
2
ASND icon
Ascendis Pharma A/S
ASND
+$15.3M
3
GYRE icon
Gyre Therapeutics
GYRE
+$7.59M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$7.42M
5
ARWR icon
Arrowhead Research
ARWR
+$6.84M

Sector Composition

Rank Sector Weight
1 Healthcare 89.69%
2 Miscellaneous 10.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
76
CALL
DELISTED
Aerie Pharmaceuticals
AERI
– –
-30,000
Closed -$1.63M
TWTR
77
CALL
DELISTED
Twitter, Inc.
TWTR
– –
-50,000
Closed -$1.45M
TWTR
78
PUT
DELISTED
Twitter, Inc.
TWTR
– –
-25,000
Closed -$725K
AMPE
79
PUT
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
– –
-1,083
Closed -$1.1M
ENDP
80
PUT
DELISTED
Endo International plc
ENDP
– –
-60,000
Closed -$356K
NBRV
81
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-2,239
Closed -$2.81M
RARX
82
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
– –
-270,000
Closed -$1.43M
NVTR
83
DELISTED
Nuvectra Corporation Common Stock
NVTR
– –
-66,724
Closed -$869K
TSRO
84
CALL
DELISTED
TESARO, Inc.
TSRO
– –
-25,000
Closed -$1.43M
ARMO
85
DELISTED
ARMO BioSciences, Inc. Common Stock
ARMO
– –
-80,000
Closed -$2.99M
AVXS
86
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-60,000
Closed -$7.42M
BEAT
87
DELISTED
BioTelemetry, Inc.
BEAT
– –
-40,000
Closed -$1.24M
1 2 3
4

Similar funds

FPC
Flax Pond Capital Falmouth, Massachusetts $143M AUM
WWM
Woodside Wealth Management Framingham, Massachusetts $144M AUM 22.2% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
BOM
Bank of Marin Novato, California $143M AUM 26.89% 1-Year Est. Return
PWM
Pathway Wealth Management Dallas, Texas $143M AUM
FF
Fox Financial Wyomissing, Pennsylvania $144M AUM 28.05% 1-Year Est. Return
JPT
Jordan Park Trust Portsmouth, New Hampshire $143M AUM 15.59% 1-Year Est. Return
BJF
Blue Jean Financial Albany, New York $144M AUM

Acuta Capital Partners's Q2 2018 Portfolio in Review

As of Q2 2018, Acuta Capital Partners held 88 positions worth $562M, down 8.3% from $612M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Acuta Capital Partners's Q2 2018 filing shows 30 new, 9 increased, 14 reduced and 29 closed positions. Its largest new stake was Madrigal Pharmaceuticals: 34,803 shares worth $9.73M. The largest sale was Immunomedics Inc, an estimated $22.1M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 77% a quarter earlier, followed by Miscellaneous.

  • Acuta Capital Partners's largest Q2 2018 buy was Madrigal Pharmaceuticals: 34,803 shares worth $9.73M.
  • Acuta Capital Partners added most to Kadmon Holdings, Inc. in Q2 2018, an estimated $12.1M increase.
  • Acuta Capital Partners's biggest Q2 2018 reduction was Immunomedics Inc, cutting an estimated $22.1M.
  • Acuta Capital Partners fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $7.42M.
  • Acuta Capital Partners's ten largest holdings make up 68% of its $562M portfolio in Q2 2018.
  • Acuta Capital Partners opened 30 new positions and closed 29 in Q2 2018.
  • Acuta Capital Partners's portfolio value fell 8.3% quarter-over-quarter to $562M.

Based on Acuta Capital Partners's 13F filing for Q2 2018, filed 15 Aug 2018.